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Abstract
Background: The aim of our study was to investigate the predictive value of the biomarkers interleukin 6 (IL-6),
interleukin 10 (IL-10) and lipopolysaccharide-binding protein (LBP) compared with clinical CRB and CRB-65 severity
scores in patients with community-acquired pneumonia (CAP).
Methods: Samples and data were obtained from patients enrolled into the German CAPNETZ study group.
Samples (blood, sputum and urine) were collected within 24 h of first presentation and inclusion in the CAPNETZ
study, and CRB and CRB-65 scores were determined for all patients at the time of enrollment. The combined end
point representative of a severe course of CAP was defined as mechanical ventilation, intensive care unit treatment
and/or death within 30 days. Overall, a total of 1,000 patients were enrolled in the study. A severe course of CAP
was observed in 105 (10.5%) patients.
Results: The highest IL-6, IL-10 and LBP concentrations were found in patients with CRB-65 scores of 3-4 or CRB
scores of 2-3. IL-6 and LBP levels on enrollment in the study were significantly higher for patients with a severe
course of CAP than for those who did not have severe CAP. In receiver operating characteristic analyses, the area
under the curve values for of IL-6 (0.689), IL-10 (0.665) and LPB (0.624) in a severe course of CAP were lower than
that of CRB-65 (0.764) and similar to that of CRB (0.69). The accuracy of both CRB and CRB-65 was increased
significantly by including IL-6 measurements. In addition, higher cytokine concentrations were found in patients
with typical bacterial infections compared with patients with atypical or viral infections and those with infection of
unknown etiology. LBP showed the highest discriminatory power with respect to the etiology of infection.
Conclusions: IL-6, IL-10 and LBP concentrations were increased in patients with a CRB-65 score of 3-4 and a severe
course of CAP. The concentrations of IL-6 and IL-10 reflected the severity of disease in patients with CAP. The
predictive power of IL-6, IL-10 and LBP for a severe course of pneumonia was lower than that of CRB-65. Typical
bacterial pathogens induced the highest LBP, IL-6 and IL-10 concentrations.
Keywords: Interleukin-6, Interleukin-10, LBP, CAP, Pneumonia, Biomarker, Cytokine
* Correspondence: frank@buehling.net
5Department of Pneumology, Hannover Medical School, Carl-Neuberg-
Strasse 1, 30625 Hannover, Germany
Full list of author information is available at the end of the article
Zobel et al. BMC Pulmonary Medicine 2012, 12:6
http://www.biomedcentral.com/1471-2466/12/6
© 2012 Zobel et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.Background
Community-acquired pneumonia (CAP) is the most
common potentially fatal infectious disease in industria-
lized countries [1,2]. In order to classify pneumonia
severity and to guide treatment decisions, several prog-
nostic scores for CAP have been developed. The CURB-
65 and CRB-65 scores are currently the preferred scores
in Europe because of their simplicity and applicability.
The CRB score has been shown to be less useful for the
estimation of the risk of death within 30 days [3,4].
A variety of pro- and anti-inflammatory cytokines are
involved in the regulation of the inflammatory response
to pulmonary infections; measurements of these cyto-
kines have been used to improve diagnosis and assess
severity, and thus predict the prognosis of CAP. The
concentrations of interleukin 6 (IL-6) [5] and interleukin
10 (IL-10) [6] reflect inflammatory and anti-inflamma-
tory reactions, respectively. The concentration of lipopo-
lysaccharide-binding protein (LBP) is increased during
bacterial infections [7].
IL-6 is secreted by a variety of cells such as T-lympho-
cytes, macrophages, endothelial cells and epithelial cells.
In inflammatory reactions the rise of IL-6 concentration
precedes that of most of the other cytokines [5,7-9] and
it has a plasma half-life of 20-60 min. IL-10 is an anti-
inflammatory cytokine that is produced primarily by
monocytes and to a lesser extent by Th-2 lymphocytes.
IL-10 inhibits the synthesis of pro-inflammatory cyto-
kines and suppresses antigen presentation, and normal
serum half-life is only a few hours [6]. LBP is an acute-
phase protein that is increased 30-fold within 24-48 h of
infection [7] and it forms complexes with bacterial lipo-
polysaccharides. These complexes bind to specific recep-
tors on monocytes and macrophages and boost
inflammation. The serum half-life of LBP is 2-4 h.
The aim of our study was to investigate the predictive
value of IL-6, IL-10 and LBP compared with the CRB-
65 score with respect to the clinical course of CAP and
the microbial etiology.
Methods
Study population
CAPNETZ is a German competence network for the
study of CAP. It collects data and samples (blood, urine
and sputum) from patients with proven CAP (hospita-
lized patients and outpatients). The network consists of
local clinical centers throughout Germany [1].
Samples and patient data were obtained from CAP-
NETZ study group. All cases of CAP were reported, via
a network of sentinel practices and hospitals, to the
study monitor of the corresponding local clinical center.
The recruitment period for the present study was
January 2001 to December 2006. A total of 3,220
subjects were selected from the database. The popula-
tion included 105 subjects with a severe course of
CAP, which was defined as mechanical ventilation,
intensive care unit (ICU) treatment and/or death
within 30 days of involvement. These 105 subjects, and
a random sample of 895 controls stratified for CRB-65
score, were included in the study. The control group
was defined using the algorithm described as follows.
First, the total number of evaluable cases was deter-
mined, n = 105. The total size of the study population
was chosen in order to get 1,000 probes for analysis.
Thus with 105 cases, 895 controls had to be selected.
For the selection of the control sample population, the
number of subjects with CRB-65 0-3 was fixed to
match the frequency distribu t i o no fC R B - 6 5i na l lc o n -
trols. Then, the respective controls were selected from
all controls in each CRB-65 stratum using the random
number generator of SPSS software (SPSS, Chicago,
Illinois, USA).
Samples (blood, sputum and urine) were taken within
24 h of first presentation and inclusion in the CAP-
NETZ study.
The inclusion criteria were: age ≥ 18 years, a new pul-
monary infiltrate diagnosed by chest radiograph, written
informed consent prior to inclusion in the study, and at
least one of the following clinical symptoms: cough with
purulent sputum, fever or positive auscultation.
The exclusion criteria were: acquired or therapeuti-
cally induced immune deficiency, active tuberculosis, or
hospitalization less than 4 weeks prior to infection.
The decision where (inpatient or outpatient) and how
to treat the patient was made by the attending physician.
All patients were assessed at first presentation and
during follow-up according to a standardized web-based
data sheet. After 14, 28 and 180 days, all patients were
contacted either in person or via telephone for a struc-
tured interview on outcome parameters (for example:
resolution of symptoms, length of antimicrobial therapy
or death) [10,11].
The CAPNETZ project was approved by the local
ethics committee. Written informed consent was
obtained from each patient prior to his/her inclusion in
the study.
Determination of CRB and CRB-65 scores
For all patients the CRB and CRB-65 scores were deter-
mined on inclusion in the study [10]. The CRB score
consists of three variables: confusion, respiratory rate ≥
30/min, and systolic blood pressure < 90 mmHg or dia-
stolic blood pressure ≤60 mmHg. The CRB-65 score
adds age ≥ 65 years to the CRB score, and one point is
given for each parameter present. CRB scores range
from 0 to 3, and CRB-65 scores range from 0 to 4.
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All serum samples to be tested for IL-6, LBP and IL-10
were stored at -70°C. The cytokine concentrations were
measured using a solid-phase, two-site chemilumines-
cence immunometric assay on Immulite 1000 (LBP and
IL-10) or Immulite 2000 (IL-6; Siemens Healthcare,
Eschborn, Germany) according to the manufacturer’s
instructions. The detection limits are 1.2 μg/ml, 0.99 pg/
ml and 2 pg/ml for LBP, IL-10 and IL-6, respectively.
Microbiologic diagnosis
Potential pathogens were detected using microbiologic,
serologic and molecular biological standard procedures,
as described previously [11,12]. Streptococcus pneumo-
niae, Haemophilus influenzae, Klebsiella pneumoniae,
Escherichia coli and other enterobacterial species, Pseu-
domonas aeruginosa, Moraxella catarrhalis and Steno-
trophomonas maltophilia were regarded as definite
causative pathogens when they were isolated from: (1)
blood cultures or pleural fluid cultures, or (2) good-
quality sputum containing < 25 polymorphonuclear cells
and < 10 epithelial cells per high-power field (total mag-
nification × 1,000), and there was predominant growth
from culture of the sputum of > 10
6 colony-forming
units (CFU)/ml or > 10
4 CFU/ml from bronchoalveolar
lavage fluid. If one of these criteria was not met, the
presence of any of the bacteria listed above was judged
to be indeterminate. In addition, Chlamydia pneumo-
niae (IgM positive ≥ 1:32 and/or positive PCR), Legio-
nella spp. (culture, positive urinary antigen and/or
PCR), Mycoplasma pneumoniae (PCR), S. pneumoniae
(urinary antigen), influenza A and B viruses, respiratory
syncytial virus, adenovirus, enterovirus (all PCR) and
Aspergillus spp. (only with concomitant lung abscess
and/or histologic confirmation) were considered to be
causative pathogens.
Statistics
Statistical analyses were performed with SPSS software.
Two-group comparisons of non-parametric data were
calculated by using a t-test. For multigroup compari-
sons, one-way ANOVA with Bonferroni post-hoc ana-
lyses were used. No correction for multiple testing was
applied with respect to the three cytokines (IL-6, IL-10
and LBP). The operating characteristics of IL-6, IL-10
and LBP were assessed by calculating sensitivity, specifi-
city and predictive values.
We constructed receiver-operating characteristic
(ROC) curves and determined the area under the
curve (AUC). The combination of parameters was
done using the linear predictor obtained from logistic
regression analysis. Thus, no categorization was
applied. The usefulness of the markers for improving
the prediction by CRB-65 score was evaluated by
calculation of continuous net reclassification improve-
ment (NRI) as described by Pencina et al. [13,14].
Thus, we looked at the rates of increased and
decreased event probability for each subject without
applying a categorization.
P values below 0.05 (two-sided) were considered to be
statistically significant. A comparison of ROC curves
w a sd o n eb yu s i n gt h em e t h o do fD e L o n g[ 1 5 ] ,w h i c h
takes into account the correlation of measurements and
increases the power considerably, compared with the
‘naïve’ method, which uses raw standard errors.
Samples from patients who did not have a severe
course of CAP were used for all controls, but the per-
centage of patients with a severe course of CAP was
about threefold (10.5% versus 3.3%) more in the final
study population as compared with that in the primary
sample of 3,220 subjects. Thus, sensitivity and specificity
of scores could be determined without further correc-
tion; however, predictive values had to be corrected
using the formula of Bayes.
Results
Patients
Epidemiology
Overall, a total of 1,000 patients with a mean age of 58.7
± 18 years (range 18-95 years) were enrolled in the
study. Of these, 565 patients were men and 435 were
women. A total of 596 patients were hospitalized and
404 patients were treated as outpatients. One hundred
and five patients (75 men, 30 women) were found to
have a severe course of CAP, defined as mechanical ven-
tilation, ICU treatment, and/or death within 30 days of
involvement. Forty-seven of the 49 ICU patients needed
mechanical ventilation and eight patients died within 30
days. Fifty-six patients who were not treated in the ICU
died within 30 days.
Distribution of CRB-65 scores
The numbers of patients with different CRB and CRB-
65 risk scores are given in Table 1.
We identified 277 patients who had received antibiotic
pretreatment within 28 days before enrollment in the
study. The CRB-65 score was significantly lower in
patients who had antibiotic pretreatment (0.64 ± 0.717)
compared with those who did not have pretreatment
(0.81 ± 0.782, P < 0.002).
The concentrations of LBP and IL-10 were signifi-
cantly lower in patients who had antibiotic pretreatment
(18.78 ± 13.3 μg/ml and 4.35 ± 5.69 pg/ml, respectively)
compared with patients who did not (22.81 ± 16.73 μg/
ml, P < 0.001, and 6.98 ± 18.73 pg/ml, P < 0.022). The
difference in IL-6 concentration was close to signifi-
cance in patients who had pretreatment (72.19 ± 332.71
pg/ml) compared with those who had not had pretreat-
ment (202.91 ± 1, 102.57 pg/ml, P = 0.053).
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Median concentrations of IL-6 and LBP on patient
enrollment were significantly higher in patients with a
severe course of CAP compared with patients who did
not have a severe course of CAP (54.4 pg/ml versus
16.6 pg/ml, P < 0.001, and 24.3 μg/ml versus 17.4 μg/ml,
P < 0.001, respectively; Figure 1A,B). The difference
in IL-10 concentrations was close to significance
(P = 0.053; Figure 1C).
High CRB-65 and CRB (data not shown) scores were
associated with a severe course of pneumonia. Figure 2
shows that IL-6, IL-10 and LBP levels in patients with
C R B - 6 5s c o r e0w e r es i g n i f i c a n t l yl o w e rt h a nt h o s ei n
patients with CRB-65 score 3-4 (P < 0.001). The respec-
tive median values were: 9.92 pg/ml versus 127.5 pg/ml
for IL-6, 1.9 pg/ml versus 9.5 pg/ml for IL-10, and 16.45
μg/ml versus 23.95 μg/ml for LBP. There was also a sig-
nificant difference (P < 0.001) between IL-6 and IL-10
concentrations in patients with CRB-65 score 1-2 and
those with CRB-65 score 3-4 (median values: 25.1 pg/ml
versus 127.5 pg/ml, and 3.2 pg/ml versus 9.5 pg/ml,
respectively).
Predictive potential of cytokines
ROC curves illustrate the accuracy of IL-6, LBP and IL-
10 concentrations, and CRB-65 and CRB scores, in pre-
dicting a severe course of pneumonia (Figure 3A,B). The
best discriminatory power was shown by a combination
of CRB-65 score and IL-6 concentration (AUC 0.800),
and a combination of CRB score and IL-6 (AUC 0.765).
The AUC for IL-6 was 0.689, which demonstrated mod-
erate discriminatory power. The AUC values for LBP
(0.624) and IL-10 (0.665) were lower. The combined use
of IL-6, LBP and IL-10 (AUC 0.689) or IL-6/IL-10 ratio
(AUC 0.63) did not significantly improve the accuracy
to predict events, compared with IL-6, LBP or IL-10
alone. CRB-65 score alone had a higher discriminatory
power, with an AUC of 0.764. The operating character-
istics of the CRB score were similar to those of the cyto-
kines (AUC 0.701).
In addition, the accuracy of cytokine concentrations in
predicting death within 30 days and mechanical ventila-
tion were analyzed separately with a lower statistical
power because of the lower number of events. The best
discriminatory power for death within 30 days was
shown with IL-6 (AUC 0.646; 95% CI 0.579 to 0.714; P
< 0.0001). CRB-65 score alone had a lower discrimina-
tory power, with an AUC of 0.626 (95% CI 0.548 to
0.705; P < 0.001). The AUC values for IL-10 (0.574) and
LBP (0.567) were not significantly different from 0.50.
IL-10 had a better discriminatory power for mechanical
ventilation (AUC 0.710; 95% CI 0.598 to 0.813; P <
0.0001) compared with IL-6 (AUC 0.644; 95% CI 0.503
to 0.784; P < 0.0001). CRB-65 score alone had a higher
discriminatory power for this mechanical ventilation,
with an AUC of 0.777 (95% CI 0.669 to 0.884; P <
0.001). The AUC for LBP (0.612) was not significant.
Based on the finding that a combination of IL-6 con-
centration and CRB-65 score had the best discrimina-
tory power, we calculated whether the addition of IL-6
concentration to CRB-65 score improved the classifica-
tion of individual patients by calculating the NRI. Using
IL-6 in addition to CRB-65, we obtained an NRI of 0.21
(CI 0.02 to 0.40) for patients who reached the combined
end point representative of a severe course of CAP and
an NRI of 0.15 (CI 0.09 to 0.21) for the control group.
The NRI for the complete population (a combination of
the NRI of the controls and the patients with the com-
bined end point) was increased significantly (0.36, CI
0.16 to 0.56). The addition of IL-6 led to an up classifi-
cation of 60.6% of patients with a severe course of CAP
and a down classification of 57.4% of control patients
(Table 2) and thus improved the categorization.
The optimal cut-off concentrations that showed the
highest prognostic accuracy (highest sensitivity and spe-
cificity) for IL-6, LBP and IL-10 in predicting a severe
course of pneumonia were calculated using data from
the ROC analyses. These data and the corresponding
positive and negative predictive values are given in
Table 3.
Microbiologic findings
The causative pathogen was identified in 321 (32.1%) of
the patients. There was no significant difference (P =
0.537) in the rate of identification of causative pathogens
in patients with antibiotic pretreatment (33.6%) com-
pared with those without pretreatment (31.5%). The
number of patients with known etiology was higher in
severe courses of pneumonia (42.9% versus 30.8%, P =
0.013).
As shown in Tables 4 and 5, we identified 98 patients
with typical bacterial infections, 155 patients with atypi-
cal bacterial infections, 23 patients with viral infections,
and 45 patients with mixed infections. Mixed infections
Table 1 Numbers of patients with defined risk scores for
CRB and CRB-65, and the corresponding number of
patients with a severe course of CAP defined as
mechanical ventilation, intensive care unit (ICU)
treatment and/or death within 30 days of involvement
Risk
score
CRB CRB-65
Total
no.
No. with severe
course
Total
no.
No. with severe
course
0 727 41 418 11
1 242 50 425 43
2 28 11 135 39
3-4 3 3 22 12
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patients), two atypical bacteria (five patients), typical
and atypical bacteria (19 patients), typical bacteria and
virus (10 patients), and atypical bacteria and viruses
(four patients).
Cytokine concentrations in patients with different
infections
The highest cytokine concentrations were found in
patients who were infected with typical bacteria such as
S. pneumoniae. In Figure 4 the cytokine concentrations
in patients with typical, atypical, viral and mixed infec-
tions are compared with those in patients infected with
unknown pathogens.
We found significant differences in IL-6, IL-10 and
LBP concentrations between patients with unknown
pathogens and those with typical bacterial infections.
The median values for IL-6 were 16.9 pg/ml versus 29.4
pg/ml (P = 0.042). The respective values for IL-10 were
2.4 pg/ml versus 4.2 pg/ml (P =0 . 0 3 3 ) ,a n df o rL B P
they were 16.9 μg/ml versus 23.25 μg/ml (P <0 . 0 0 1 ) .I n
addition, significant differences in the LBP concentra-
tions were found in patients with typical (23.25 μg/ml)
and atypical bacterial infections (18.7 μg/ml, P <0 . 0 1 2 ) .
We found 33 patients with Gram-negative and 65
patients with Gram-positive typical bacterial infections.
Median LBP levels in patients with pneumonia caused
by Gram-negative organisms were significantly lower
(18.10 ± 11.76 μg/ml) compared with patients with
pneumonia caused by Gram-positive bacteria (28.40 ±
25.38 μg/ml; P < 0.001). The IL-6 and IL-10 concentra-
tions were similar in both patient groups.
Discussion
This study demonstrated: (1) IL-6 and IL-10 concentra-
tions at the time of patient admission reflected, similar
to the CRB score, the severity of disease rather than
prognosis, which is influenced not only by severity but
also by age and co-morbidities of the patients; therefore,
high IL-6 and/or IL-10 concentrations were found in
patients with high CRB or CRB-65 scores; (2) the bio-
markers used were inferior to CRB-65 score, but similar
to the CRB score, for predicting a severe course of CAP;
(3) the accuracy of both CRB and CRB-65 for predicting
a severe course of pneumonia could be increased signifi-
cantly by including the IL-6 measurements in a statisti-
cal model; (4) LBP had some predictive potential in
etiology, but individual predictions could not be made.
Current CAP guidelines recommend that patients at
increased risk of death should be hospitalized, and that
ICU admission should be considered for patients with
the highest risk. To date, several different pneumonia
Figure 1 Levels of cytokines in the course of community-
acquired pneumonia. (A) Interleukin 6 (IL-6), (B)
lipopolysaccharide-binding protein (LBP), and (C) interleukin 10 (IL-
10). Boxes: horizontal lines indicate 25th to 75th percentiles, and
whiskers indicate median, 2.5th and 97.5th percentiles. CAP,
community-acquired pneumonia.
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CURB, CURB-65, CRB and CRB-65, have been evaluated
[16-18]. In addition, new biomarkers such as procalcito-
nin (PCT), proatrial natriuretic peptide (pro-ANP,
copeptin), proatrial vasopressin (proAVP), proadrenome-
dullin (proADM) and proendothelin-1 (proET1) have
been found to have similar, additive or superior predic-
tive values for the risk assessment of CAP [19,20].
IL-6 and IL-10 play an important role in regulation of
inflammatory reactions. Various studies have shown
increased concentrations of these cytokines during
pneumonia [21-24]. Elevated IL-6 and IL-10 levels have
been directly associated with higher mortality, ICU
admission and mechanical ventilation [25,26].
Increased LBP concentrations have been found in
patients with severe sepsis caused by Gram-negative or
Gram-positive bacterial infections or fungal infections
[25,26]. Data concerning LBP concentration in CAP are
scarce [27,28].
In contrast to most of the studies that have been pub-
lished so far, we investigated the concentrations of IL-6,
IL-10 and LBP in comparison with clinical and
microbiologic findings in a large and carefully character-
ized study population, which included a large number of
patients with a severe course of CAP; this was defined
as mechanical ventilation, ICU treatment and/or death
within 30 days of involvement.
In patients with a severe course of pneumonia, we
found significantly increased IL-6 and LBP concentra-
tions. In contrast to previous studies, which found new
biomarkers such as PCT, pro-ANP, proAVP, proET1
and proADM to be good predictors of the course and
the outcome of CAP, and which were similar or super-
ior to CRB-65 score, we found a lower predictive poten-
tial for IL-6, IL-10 and LBP. As published recently, the
predictive value of CRP was also lower than that of the
CRB-65 score [10]. We were able to confirm these find-
ings by calculating an AUC of 0.663 for differentiation
of the combined end point and CRP (data not shown).
The combination of CRB-65 score and IL-6 concentra-
tion increased the predictive value. This finding may be
of limited value for the risk stratification of individual
patients as there was a significant overlap in the distri-
bution of IL-6 concentration in different patient groups
Figure 2 Levels of cytokines and CRB-65 class on patient admission in community-acquired pneumonia. (A) Interleukin 6 (IL-6), (B)
lipopolysaccharide-binding protein (LBP), and (C) interleukin 10 (IL-10). Continuous lines denote median values, boxes represent 25th to 75th
percentiles and whiskers indicate 2.5th and 97.5th percentiles. CAP, community-acquired pneumonia.
Figure 3 Receiver-operating characteristic curves to predict a severe course of community-acquired pneumonia and high CRB-65 or
CRB scores. (A) Receiver operator characteristic (ROC) curves for interleukin 6 (IL-6; area under curve (AUC) 0.689; 95% CI 0.636 to 0.741; P <
0.001), lipopolysaccharide-binding protein (LBP; AUC 0.624; 95% CI 0.567 to 0.681; P < 0.0001), interleukin 10 (IL-10; AUC 0.665; CI 0.611 to 0.718;
P < 0.0001), CRB score (AUC 0.701; 95% CI 0.643 to 0.760; P < 0.0001) and CRB-65 score (AUC 0.764; 95% CI 0.716 to 0.812; P < 0.0001), and (B)
combination of CRB-65 score plus IL-6 concentration (AUC 0.800; 95% CI 0.759 to 0.842; P < 0.0001) and CRB score plus IL-6 concentration (AUC
0.765; 95% CI 0.720 to 0.810; P < 0.0001), in predicting a severe course of community-acquired pneumonia (CAP).
Zobel et al. BMC Pulmonary Medicine 2012, 12:6
http://www.biomedcentral.com/1471-2466/12/6
Page 6 of 10[29]. Therefore, to test the value of IL-6 for the improv-
ing risk prediction we calculated the NRI for IL-6 in
combination with CRB-65 score and compared it with
CRB-65 score alone and found a significant net gain in
reclassification by including IL-6.
On the other hand, we found a strong association
between the IL-6 and IL-10 concentrations and high
CRB scores (class 2-3). The operational characteristics
of IL-6, IL-10 and CRB with respect to a severe course
of CAP were similar to each other.
There are several factors that may reduce the prog-
nostic potential of these parameters. First, the induction
of IL-6 secretion precedes that of most other pro-
inflammatory cytokines and is strongly controlled by
anti-inflammatory cytokiness u c ha sI L - 1 0 .S e c o n d ,a l l
cytokines investigated in our study have a short plasma
half-life of a few hours. Previous studies have shown
that the mean levels of IL-6 and IL-10 decrease rapidly
after clinical presentation in response to therapeutic
interventions [30-32]. Thus,I L - 6a n dI L - 1 0a r ec y t o -
kines that characterize the acute clinical condition of
patients. Therefore, and with respect to the high nega-
tive predictive values of 0.984, 0.981 and 0.978 for IL-6,
IL-10 and LBP, respectively, normal cytokine concentra-
tions might be used to identify patients who can be trea-
ted as outpatients.
Similar to our results, previous studies have shown
that the CRB score fails to predict many severe courses
of CAP. Consequently, it has been suggested that age ≥
65 years should be included to identify patients at high
risk because of potential comorbidities [25,26]; the
resulting CRB-65 score has been shown to useful in
characterizing the acute clinical condition and the risk
of a severe course of CAP.
Table 2 Reclassification of patients based on the IL-6
concentration
Patients Classification
Down Up
Control 514 (57,4%) 381 (42,6%)
Severe course of CAP 41 (39,4%) 63 (60,6%)
Table 3 Optimal cut-off values for cytokines, with
sensitivity, specificity and positive and negative
predictive values
Cut-off value Sensitivity Specificity PPV NPV
Interleukin-6 27.2 pg/ml 70.5 60.4 0.057 0.984
Interleukin-10 3.15 pg/ml 67.3 58.1 0.051 0.981
LBP 22.45 μg/ml 55.2 66.6 0.053 0.978
Positive predictive values (PPV) and negative predictive values (NPV) were
obtained using Bayes’ formula, with a prevalence of 0.0326. LBP,
lipopolysaccharide-binding protein.
Table 4 Microbiologic findings for all patients
Microbial etiology Number of patients
Inpatients Outpatients Total
Typical bacteria 65 33 98
Streptococcus pneumonia 39 17 56
Haemophilus influenzae 58 1 3
Escherichia coli 31 4
Staphylococcus aureus 53 8
Moraxella catarrhalis 11 2
Enterobacter spp. 2 1 3
Pseudomonas aeruginosa 60 6
Citrobacter spp. 0 1 1
Klebsiella pneumoniae 10 1
Streptococcus pyogenes 10 1
Prevotella spp. 1 0 1
Acinetobacter spp. 0 1 1
Hafnia alvei 10 1
Atypical pathogens 87 68 155
Mycoplasma pneumoniae 59 60 119
Legionella spp. 28 8 36
Viruses 9 14 23
Adenovirus 1 1 2
Influenza A 5 7 12
Influenza B 1 2 3
Respiratory syncyntial virus 1 3 4
Enterovirus 1 1 2
Mixed organisms 30 15 45
Unknown organism(s) 405 274 679
Table 5 Microbiologic findings for patients with severe
pneumonia
Microbial etiology Number of patients
Inpatients Outpatients Total
Typical bacteria 18 1 19
Streptococcus pneumonia 80 8
Haemophilus influenza 31 4
Escherichia coli 10 1
Staphylococcus aureus 20 2
Enterobacter spp. 1 0 1
Pseudomonas aeruginosa 20 2
Streptococcus pyogenes 10 1
Atypical pathogens 19 2 21
Mycoplasma pneumonia 10 2 12
Legionella spp. 9 0 9
Viruses 1 0 1
Influenza A 1 0 1
Mixed organisms 4 0 4
Unknown organism(s) 60 0 60
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proET1 or MR-proANP, or adrenomedullin (MR-
proADM) which has multiple effects, reflect at least in
part non-pulmonary comorbidities [19,20]. These bio-
markers have the highest predictive value for death
within 30 or 180 days. Inflammatory biomarkers such as
PCT, which has a delayed concentration kinetic, have an
intermediate predictive value that is comparable with
the clinical CRB-65 score. We have shown that inflam-
matory markers that are rapidly regulated have a low
predictive value that is comparable with that of the CRB
score. Further studies should answer the questions: (1)
does a combination these biomarkers with a cardiovas-
cular marker further improve the prediction of the
course of CAP, and (2) can these biomarkers be used to
monitor disease progression? The latter question is not
addressed within the CAPNETZ study because the tim-
ing of the biomarker measurements is not standardized,
except that the blood samples were collected within 24
h after presentation at the study center. Under these
conditions biomarkers that have short peak concentra-
tions at defined disease states may have lower prognos-
tic values compared with those with long-lasting
elevated concentrations.
In CAP, the determination of the etiology of the
microbial pathogen is essential to target therapeutic
decisions. In our study population the etiology remained
unknown in 67.9% of the patients; this is comparable
with previous findings [11]. It has been suggested that
diagnostic sensitivity is reduced by antibiotic pretreat-
ment prior to hospital admission. For example, typical
pathogens such as S. pneumoniae a r ee a s i l ym i s s e da f t e r
as i n g l ed o s eo fa n t i m i c r o b i al treatment [11,33]. In our
study we found no association between antibiotic pre-
treatment and identification of etiologic microbial
pathogen. The identification rate was higher patients
with a severe course of pneumonia.
The highest concentrations of LBP, IL-6 and IL-10
were found in patients infected with typical bacteria. In
previous studies, elevated IL-6 concentrations were
found in patients infected with S. pneumoniae [24,34].
The concentration of the anti-inflammatory IL-10 was
increased in parallel to the increase in pro-inflammatory
IL-6, and this reflects the amplification of antimicrobial
as well as host-protective processes in CAP [35,36].
In our study, the LBP concentration was the best
parameter to differentiate between typical and atypical
or viral pathogens, and we found significantly higher
LBP concentrations in patients with typical bacterial
infections. In addition, in our study population, we
found significantly higher LBP concentrations in patients
with atypical infections compared with patients infected
Figure 4 Levels of cytokines on admission in patients with
community-acquired pneumonia, and microbial etiology.
Microbial etiology was infection with typical bacteria, atypical
bacteria, viruses or mixed organisms, or unknown etiology. The
scatter plots represent all data. Median values with interquartile
ranges are shown.
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Page 8 of 10with an unknown pathogen. Masia et al. found LBP
concentrations to be similar in patients infected with
unknown pathogens, compared with those with viral
and atypical infections [37]. Within the group of typical
bacterial infections, we found higher LBP concentrations
in patients infected with Gram-positive bacteria. This
supports the previous finding that LBP is a non-specific
marker of bacterial infection [25,26].
Conclusions
In conclusion, we have shown that IL-6, LBP and IL-10 are
biomarkers that are significantly increased in severe CAP.
Increased IL-6 and IL-10 concentrations reflect an acute
inflammation at time of admission and are associated with
high CRB and CRB-65 scores. The predictive value for a
severe course of CAP, defined by death, admission to ICU
or mechanical ventilation, was lower than that of the CRB-
65 score. However, the accuracy of both CRB and CRB-65
scores could be increased significantly by including the IL-
6 measurements in the statistical model. IL-6 and IL-10
represent, with respect to CAP, a group of biomarkers that
reflect the current clinical condition (that is, severity of dis-
ease) of patients; this is different from previously studied
biomarkers, such as pro-ANP or proADM, which reflect
cardiovascular comorbidities, and PCT, which might reflect
persisting inflammatory reactions. LBP appeared to be the
best parameter to predict a typical bacterial infection.
Further studies should address the question of whether the
predictive value can be improved by combined measure-
ment of biomarkers from different groups, and whether
these cytokines are useful biomarkers to monitor disease
progression and response to therapeutic interventions.
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